Miconazole%25252525252525252525252525252520vaginal%25252525252525252525252525252520pessary

# Miconazole Vaginal Pessary ## Overview Miconazole is a synthetic imidazole antifungal agent that inhibits fungal growth by impairing the synthesis of ergosterol, a vital component of fungal cell membranes. ## Primary Indications Treatment of vulvovaginal candidiasis (yeast infection). ## Adult Dosing * **100 mg vaginal pessary:** Insert one pessary vaginally at bedtime for 7 days. * **200 mg vaginal pessary:** Insert one pessary vaginally at bedtime for 3 days. * **100 mg vaginal suppositories:** Insert one suppository vaginally at bedtime for 7 days. * **200 mg vaginal suppositories:** Insert one suppository vaginally at bedtime for 3 days. * **1% vaginal cream (applicatorful equivalent to 100 mg):** Insert one applicatorful (100 mg) vaginally at bedtime for 7 days. * **2% vaginal cream (applicatorful equivalent to 100 mg):** Insert one applicatorful (100 mg) vaginally at bedtime for 3 days. *Dosing may vary based on the specific product formulation and severity of infection. Consult product labeling for specific instructions.* ## Pediatric Dosing * **Pediatric patients (under 12 years of age):** Safety and efficacy have not been established. Generally, miconazole vaginal products are not recommended for children under 12 years of age without specific medical guidance and supervision. ## Dose Adjustments No dose adjustments are typically required based on renal or hepatic impairment, as systemic absorption is minimal with vaginal administration. ## Contraindications * Hypersensitivity to miconazole or any component of the formulation. ## Adverse Effects * **Common:** Vulvovaginal burning, itching, irritation, abdominal cramps. * **Less Common:** Headache, rash. ## Key Drug Interactions * **Warfarin:** Miconazole (especially oral forms, but caution with vaginal as well due to potential systemic absorption) can inhibit CYP2C9, leading to increased warfarin levels and the risk of bleeding. Monitor INR closely if used concurrently. * **CYP3A4 Substrates/Inhibitors:** While systemic absorption is low, theoretically, concurrent use of potent CYP3A4 inhibitors or substrates could lead to altered concentrations. ## Monitoring * Monitor for signs and symptoms of vulvovaginal candidiasis. * Assess for and manage adverse effects. ## Clinical Pearls * The entire course of treatment should be completed even if symptoms improve. * Avoid intercourse during treatment. * May weaken latex condoms and diaphragms, reducing their effectiveness. * If symptoms do not improve within 3 days or persist beyond 7 days, re-evaluate diagnosis and consider alternative therapy. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Local protocols and formulary may influence drug selection and dosing.